Limited coverage criteria – secukinumab

Last updated on March 21, 2025

Special Authority requests can now be submitted online. It's simple and quick!

Generic name	secukinumab
Strength & form	150 mg/mL solution for subcutaneous injection

Special Authority criteria	Approval period
For the treatment of moderate to severe plaque psoriasis, according to established criteria described in Special Authority request form HLTH – 5380 Biologics for Moderate to Severe Plaque Psoriasis (PDF, 793KB) Coverage of secukinumab for the treatment of plaque psoriasis is only available when a Special Authority request is submitted by a dermatologist	Initial: 12 weeks Renewal: 1 year
For the treatment of ankylosing spondylitis, according to established criteria described in Special Authority request forms: Initial/switch: HLTH 5 365 Targeted DMARDs for Ankylosing Spondylitis – Initial/Switch (PDF, 817KB) Renewal: HLTH – 5 366 Targeted DMARDs for Ankylosing Spondylitis – Renewal (PDF, 820KB) Coverage of secukinumab for the treatment of ankylosing spondylitis is only available when a Special Authority request is submitted by a rheumatologist	Initial: 1 year Renewal: 1 year
For the treatment of psoriatic arthritis, according to established criteria described in Special Authority request forms: Initial/switch: HLTH – 5 360 Targeted DMARDs for Psoriatic Arthritis – Initial/Switch (PDF, 839KB) Renewal: HLTH – 5 361 Targeted DMARDs for Psoriatic Arthritis – Renewal (PDF, 831KB) Coverage of secukinumab for the treatment of psoriatic arthritis is only available when when a Special Authority request is submitted by a rheumatologist	Initial: 1 year Renewal: 1 year

Special Authority criteria

Approval period

For the treatment of moderate to severe plaque psoriasis, according to established criteria described in Special Authority request form HLTH – 5380 Biologics for Moderate to Severe Plaque Psoriasis (PDF, 793KB)

Coverage of secukinumab for the treatment of plaque psoriasis is only available when a Special Authority request is submitted by a dermatologist

Initial: 12 weeks
Renewal: 1 year

For the treatment of ankylosing spondylitis, according to established criteria described in Special Authority request forms:

Coverage of secukinumab for the treatment of ankylosing spondylitis is only available when a Special Authority request is submitted by a rheumatologist

Initial: 1 year
Renewal: 1 year

For the treatment of psoriatic arthritis, according to established criteria described in Special Authority request forms:

Initial/switch: HLTH – 5 360 Targeted DMARDs for Psoriatic Arthritis – Initial/Switch (PDF, 839KB)
Renewal: HLTH – 5 361 Targeted DMARDs for Psoriatic Arthritis – Renewal (PDF, 831KB)

Coverage of secukinumab for the treatment of psoriatic arthritis is only available when when a Special Authority request is submitted by a rheumatologist

Initial: 1 year
Renewal: 1 year

Practitioner exemptions

None

Special notes

PharmaCare covers a maximum of 30 days per fill for secukinumab

Special Authority request form(s)

Read practitioner/prescriber requirements above.

Did you find what you were looking for?

The B.C. Public Service acknowledges the territories of First Nations around B.C. and is grateful to carry out our work on these lands. We acknowledge the rights, interests, priorities, and concerns of all Indigenous Peoples - First Nations, Métis, and Inuit - respecting and acknowledging their distinct cultures, histories, rights, laws, and governments.

More topics